Monthly Archives: December 2011

Thinking about the performance of recent biotech IPOs reminds me of the Black Knight in Monty Python’s Holy Grail: not dead yet.  But even if it’s not dead, its certainly been a very challenging few years for new offerings. In

Today we announced a new strategic alliance with Shire Pharmaceutical’s to identify new opportunities for early stage venture creation aimed at addressing rare genetic diseases.  This collaboration brings unique expertise from Shire’s Human Genetic Therapies group together with our company creation

The sunk cost bias in venture capital is widely derided as a driver of poor returns in the asset class.  It’s the psychological root cause of why good money gets thrown after bad: VCs hoping for an unlikely outcome because they

Biotech’s high risks have led to the conventional wisdom that it’s valuable to construct a diversified portfolio of products at the company level.  Reinforced by the “show me multiple shots on goal” mantra of the capital markets, many product-focused biotech